Related Experiment Video
Updated: Aug 1, 2026

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
Published on: February 3, 2021
Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus
R DeBusk1, Y Drory, I Goldstein
1Stanford University School of Medicine, Palo Alto, California, USA.
Insights
Patients with cardiovascular disease and sexual dysfunction can resume sexual activity safely if they are low-risk. Intermediate-risk patients need further evaluation, while high-risk patients require cardiac stabilization first.
Area of Science:
- Cardiology
- Sexual Medicine
Background:
- Sexual dysfunction is common and impacts quality of life.
- A strong link exists between sexual dysfunction and cardiovascular disease (CVD).
- Sexual activity carries potential cardiac risks.
Purpose of the Study:
- To develop clinical management recommendations for sexual dysfunction in CVD patients.
- To stratify CVD patients by cardiac risk for sexual activity and treatment.
- To provide a physician-guided algorithm for managing sexual dysfunction in CVD.
Main Methods:
- A consensus panel reviewed research and expert presentations.
- A cardiac risk stratification system (low, intermediate, high) was developed.
- An algorithm was created to guide clinical decision-making.
Main Results:
- Most patients fall into the low-risk category (e.g., controlled hypertension, stable angina, uncomplicated MI).
- Low-risk patients can resume sexual activity or receive treatment, with caution regarding sildenafil and nitrates.
- Intermediate-risk patients require further cardiac evaluation; high-risk patients need stabilization before resuming sexual activity or treatment.
Conclusions:
- A risk-stratification approach enables safe management of sexual dysfunction in CVD patients.
- Physicians can use the provided algorithm to guide patient care.
- Addressing sexual dysfunction is crucial for improving well-being in CVD patients.
Abstract:
Sexual dysfunction is highly prevalent in both sexes and adversely affects patients' quality of life and well being. Given the frequent association between sexual dysfunction and cardiovascular disease, in addition to the potential cardiac risk of sexual activity itself, a consensus panel was convened to develop recommendations for clinical management of sexual dysfunction in patients with cardiovascular disease. Based upon a review of the research and presentations by invited experts, a classification system was developed for stratification of patients into high, low, and intermediate categories of cardiac risk. The large majority of patients are in the low-risk category, which includes patients with (1) controlled hypertension; (2) mild, stable angina; (3) successful coronary revascularization; (4) a history of uncomplicated myocardial infarction (MI); (5) mild valvular disease; and (6) no symptoms and <3 cardiovascular risk factors. These patients can be safely encouraged to initiate or resume sexual activity or to receive treatment for sexual dysfunction. An important exception is the use of sildenafil in patients taking nitrates in any form. Patients in the intermediate-risk category include those with (1) moderate angina; (2) a recent MI (<6 weeks); (3) left ventricular dysfunction and/or class II congestive heart failure; (4) nonsustained low-risk arrhythmias; and (5) >/=3 risk factors for coronary artery disease. These patients should receive further cardiologic evaluation before restratification into the low- or high-risk category. Finally, patients in the high-risk category include those with (1) unstable or refractory angina; (2) uncontrolled hypertension; (3) congestive heart failure (class III or IV); (4) very recent MI (<2 weeks); (5) high-risk arrhythmias; (6) obstructive cardiomyopathies; and (7) moderate-to-severe valvular disease. These patients should be stabilized by specific treatment for their cardiac condition before resuming sexual activity or being treated for sexual dysfunction. A simple algorithm is provided for guiding physicians in the management of sexual dysfunction in patients with varying degrees of cardiac risk.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Heart Failure V: Medical Management
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care

